Unique SNP in CD44 Intron 1 and Its Role in Breast Cancer Development

Overview

Journal Anticancer Res

Specialty Oncology

Date 2010 Jun 10

PMID 20530438

Citations 17

Authors

Juhua Zhou

Prakash S Nagarkatti

Yin Zhong

Kim Creek

Jiajia Zhang

Mitzi Nagarkatti

Affiliations

Soon will be listed here.

Abstract

In the current study, we investigated if CD44 polymorphisms are associated with increased susceptibility to breast cancer. Direct nucleotide sequencing analysis identified a novel and unique single nucleotide polymorphism (SNP, designated as CD44 Ex2+14 A>G) in the CD44 intron 1 region in 84% of breast cancer patients, which was significantly higher than that seen in normal donors. Moreover, the breast cancer patients with homozygous unique SNP in CD44 intron 1 had breast cancer at earlier ages, larger tumor burden, more regional lymph node metastases at the time of diagnosis, and higher cancer recurrence rate. There was a strong association between the unique SNP in CD44 intron 1 and CD44 expression on peripheral blood mononuclear cells. Our results suggest that CD44 polymorphism is associated with breast cancer development, and CD44 polymorphism analysis may be effectively used in the risk assessment, prediction, prevention, diagnosis and genetic epidemiological analysis of breast cancer.

Citing Articles

Impact of CD44 genetic variants on clinicopathological characteristics of uterine cervical cancer patients.

Sun Y, Wang C, Shen H, Lee C, Lin C, Yang S Int J Med Sci. 2024; 21(8):1428-1437.

PMID: 38903932 PMC: 11186425. DOI: 10.7150/ijms.96414.

Genetic Polymorphism in FSCN1 rs3801004 C/G and CD44 rs353639 A/C, as Prognostic Factor in Egyptian Breast Cancer Patients.

Ibrahim N, Hamed R, Refaat A, Mosaad Y, Mekawy D Asian Pac J Cancer Prev. 2023; 24(10):3517-3523.

PMID: 37898858 PMC: 10770661. DOI: 10.31557/APJCP.2023.24.10.3517.

Concurrent Reduced Expression of Contiguous and Leading to Kidney Diseases and Multiple Diverse Renal Cancers.

Meguro S, Koguchi T, Hakozaki Y, Onagi A, Matsuoka K, Hoshi S Cancer Genomics Proteomics. 2022; 20(1):40-50.

PMID: 36581342 PMC: 9806674. DOI: 10.21873/cgp.20363.

Association of CD44 polymorphisms and susceptibility to HBV-related hepatocellular carcinoma in the Chinese population.

Deng Y, Chen Z, Lan F, He Q, Chen S, Du Y J Clin Lab Anal. 2019; 33(8):e22977.

PMID: 31301090 PMC: 6805271. DOI: 10.1002/jcla.22977.

Association of Single-Nucleotide Polymorphisms of CD44 Gene with Susceptibility to Breast Cancer in Chinese Women.

Lin X, You X, Cao X, Pan S Med Sci Monit. 2018; 24:3077-3083.

PMID: 29748526 PMC: 5973502. DOI: 10.12659/MSM.907422.

References

Feigelson H, Rodriguez C, Jacobs E, Diver W, Thun M, Calle E . No association between the progesterone receptor gene +331G/A polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13(6):1084-5. View

De Vivo I, Hankinson S, Colditz G, Hunter D . A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res. 2003; 63(17):5236-8. View

Mitra A, Singh N, Garg V, Chaturvedi R, Sharma M, Rath S . Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to Squamous Cell Carcinomas of the Head and Neck (SCCHN) and Breast cancer in the north Indian population. J Exp Clin Cancer Res. 2009; 28:104. PMC: 2724389. DOI: 10.1186/1756-9966-28-104. View

Bourguignon L, Zhu D, Zhu H . CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci. 1998; 3:d637-49. DOI: 10.2741/a308. View

Seth A, Gote L, Nagarkatti M, Nagarkatti P . T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14. Proc Natl Acad Sci U S A. 1991; 88(17):7877-81. PMC: 52407. DOI: 10.1073/pnas.88.17.7877. View

Park J, Cai J, McIntosh I, Jabs E, Fallin M, Ingersoll R . High throughput SNP and expression analyses of candidate genes for non-syndromic oral clefts. J Med Genet. 2006; 43(7):598-608. PMC: 2564555. DOI: 10.1136/jmg.2005.040162. View

Dadi H, Greaves A, Cox D, Letarte M . Identification of a polymorphism in human CD44. Nucleic Acids Res. 1991; 19(4):969. PMC: 333762. DOI: 10.1093/nar/19.4.969-a. View

Johnatty S, Spurdle A, Beesley J, Chen X, Hopper J, Duffy D . Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies. Breast Cancer Res Treat. 2007; 109(1):91-9. DOI: 10.1007/s10549-007-9627-3. View

Nagarkatti P, Nagarkatti M . Role of CD44 in CTL and NK cell activity. Front Biosci. 1998; 3:d665-71. DOI: 10.2741/a311. View

10.

Smith E, Adams S, Das I, Bottai M, Fulton J, Hebert J . Breast cancer survival among economically disadvantaged women: the influences of delayed diagnosis and treatment on mortality. Cancer Epidemiol Biomarkers Prev. 2008; 17(10):2882-90. PMC: 2959167. DOI: 10.1158/1055-9965.EPI-08-0221. View

11.

Thompson D, Easton D . The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia. 2004; 9(3):221-36. DOI: 10.1023/B:JOMG.0000048770.90334.3b. View

12.

Terry M, Gammon M, Zhang F, Eng S, Sagiv S, Paykin A . Polymorphism in the DNA repair gene XPD, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2004; 13(12):2053-8. View

13.

Siddig A, Mohamed A, Kamal H, Awad S, Hassan A, Zilahi E . HER-2/neu Ile655Val polymorphism and the risk of breast cancer. Ann N Y Acad Sci. 2008; 1138:84-94. DOI: 10.1196/annals.1414.014. View

14.

Nagai K, Muto Y, Pomeranz Krummel D, Kambach C, Ignjatovic T, Walke S . Structure and assembly of the spliceosomal snRNPs. Novartis Medal Lecture. Biochem Soc Trans. 2001; 29(Pt 2):15-26. DOI: 10.1042/0300-5127:0290015. View

15.

Rafi A, Nagarkatti M, Nagarkatti P . Hyaluronate-CD44 interactions can induce murine B-cell activation. Blood. 1997; 89(8):2901-8. View

16.

McKallip R, Fisher M, Do Y, Szakal A, Gunthert U, Nagarkatti P . Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes. J Biol Chem. 2003; 278(44):43818-30. DOI: 10.1074/jbc.M304467200. View

17.

Bernard-Gallon D, Bosviel R, Delort L, Fontana L, Chamoux A, Rabiau N . DNA repair gene ERCC2 polymorphisms and associations with breast and ovarian cancer risk. Mol Cancer. 2008; 7:36. PMC: 2394522. DOI: 10.1186/1476-4598-7-36. View

18.

Marhaba R, Zoller M . CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004; 35(3):211-31. DOI: 10.1023/b:hijo.0000032354.94213.69. View

19.

Pharoah P, Tyrer J, Dunning A, Easton D, Ponder B . Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet. 2007; 3(3):e42. PMC: 1828694. DOI: 10.1371/journal.pgen.0030042. View

20.

Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N . Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999; 91(11):943-9. DOI: 10.1093/jnci/91.11.943. View